Skip to content

Prospective, multicenter, randomized controlled, non-inferiority clinical trial of flow diverter Repath in the treatment of intracranial aneurysm

Safety and efficiency of flow diverter Repath in the treatment of intracranial aneurysms

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034893
Enrollment
Unknown
Registered
2020-07-23
Start date
2020-08-01
Completion date
Unknown
Last updated
2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intracranial aneurysm

Interventions

Repath placement group:Repath placement with or without coiling
Tubridge placement group:Tubridge placement with or without coiling

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1)18-75 years old, male or unpregnant female; 2)Unruptured intracranial aneurysms locate in anterior or posterior circulation, including saccular aneurysms and recurrent aneurysms; 3)The aneurysm has >= 4 mm neck and >= 10 mm max diameter; 4) Parent artery diameter varies from 2.5mm to 6.0mm; 5)Suitable to be treated with Repath or Tubridge stent with or without coiling. 6) The subject or legal representatives understand the purpose of this study with good compliance and signed the consent form; 7)Subjects with intracranial aneurysms that can be stented only or coiled-assisted stented.

Exclusion criteria

Exclusion criteria: 1)Lesions with no suitable vascular approach; 2) Intracranial aneurysm associated with AVM; 3) Ruptured intracranial aneurysm; 4) Lesions not suitable for the stent navigation; 5) With planed surgery within 30 days; 6) mRS >=4; 7) Life expectancy is less than 12 months; 8) Subjects have participated in clinical trials of other drugs or medical devices and have not reached end point; 9) Subjects with poor compliance; 10) With clear history of allergy to NiTi alloy and or cobalt base alloy and platinum tungsten alloy; 11) Contraindications to dual antiplatelet therapy and anticoagulation therapy; 12) With possible or clear history of severe allergy to contrast media.

Design outcomes

Primary

MeasureTime frame
occlusion of aneurysm;

Secondary

MeasureTime frame
immediate procedure success rate;

Countries

China

Contacts

Public ContactSheng Guan

The First Affiliated Hospital of Zhengzhou University

gsradio@126.com+86 13673665399

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026